Welcome to our dedicated page for 60 Degrees Pharm SEC filings (Ticker: SXTPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
60 Degrees Pharmaceuticals filings document material-event disclosures for a specialty pharmaceutical issuer focused on vector-borne disease. Its Form 8-K reports address Nasdaq listing matters, at-the-market equity offering documentation, legal opinions related to common stock issued under the ATM program, and corrections to beneficial ownership information in offering materials.
The filings identify the company's common stock under SXTP and warrants under SXTPW, each warrant representing the right to purchase one share of common stock. They also document emerging growth company status, registered securities, capital-structure matters, and formal disclosures tied to listing compliance and public-company governance.
60 Degrees Pharmaceuticals (SXTP/SXTPW) filing an initial Form 3 showed the reporting person, Kristen Landon, Chief Operating Officer, reports no beneficial ownership of the issuer's securities. The event date triggering the report is 02/12/2024. The filing notes it was submitted late due to an inadvertent administrative error. The form is signed by Ms. Landon on 08/14/2025, and there are no listed non-derivative or derivative holdings on the schedules.
60 Degrees Pharmaceuticals is a specialty pharmaceutical company marketing the FDA-approved malaria prevention product Arakoda and developing additional tafenoquine-based and other programs. For the three months ended June 30, 2025 the company reported net revenue of $257,820 (including $100,932 product revenue and $206,939 research revenue) and a gross profit of $50,881. Cash and cash equivalents were $1,966,930 at June 30, 2025, up from $1,659,353 at December 31, 2024, aided by net financing proceeds of approximately $1.7 million from January and February 2025 registered offerings.
Despite the revenue increase, the company reported a six-month net loss of $3,612,231, used $3,047,494 in operating activities during the six months, and had an accumulated deficit of $44,138,232. Derivative liabilities tied to a contingent milestone (Knight) were $776,172. Management states there is substantial doubt about the company’s ability to continue as a going concern without raising additional capital. The company also faces customer concentration (significant customers comprised ~99% of product revenue for the quarter) and sole-vendor API supply risk.